Jinghao Wang

Mr. Jinghao Wang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Cells
Verified
Journal Article
Open access
PDF file
YXYing Xie
Ying Xie
QMQian Ma
Qian Ma
JWJinghao Wang
Jinghao Wang
ZZZoe Xiaofang Zhu
Zoe Xiaofang Zhu
RERady Elaraby
Rady Elaraby
JCJake Chen
Jake Chen
Adiponectin (APN) is a secreted adipokine that plays a key role in modulating energy and bone metabolism, as well as regulating inflammatory responses. The overexpression of APN has been proposed as a potential therapeutic strategy for treating obesity and related disorders. Lipid nanoparticles (LNPs) are promising vectors for transporting messenger ribonucleic acid (mRNA) molecules. This study tested whether delivering a stabilized version of adiponectin mRNA (APN mRNA) using lipid nanoparticles could reduce fat formation and promote bone repair in vitro and in vivo. We demonstrated that transfection with APN-LNP upregulated the mRNA and protein expression of APN, while inhibiting adipogenesis in 3T3-L1 adipocytes. APN-LNP enhanced osteogenic gene expression in MC3T3-E1 cells in a dose-dependent manner. It also reduced matrix metalloproteinase 9 expression in receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated RAW264.7 cells, suggesting an anti-resorptive effect. In vivo, a femoral fracture model was established to explore the application of APN-LNP in promoting bone healing in diet-induced obese mice. Micro-computed tomography and histology analysis indicated that intravenous injection with APN-LNP promoted bone healing. Fasting blood glucose and body weight were decreased in the APN-LNP group. Moreover, APN-LNP increased bone sialoprotein and runt-related transcription factor 2 expression in contralateral femurs, as well as interleukin-10 expression in white adipose tissues. Thus, our study provides promising preclinical data on the potential use of APN-LNP for treating bone disorders in obesity.

Verified
Journal Article
Open access
PDF file
YCYu-Chi Cheng
Yu-Chi Cheng
JWJinghao Wang
Jinghao Wang
ZGZach Gouveia
Zach Gouveia
Parham HazratiParham Hazrati
Parham Hazrati
RRRodrigo Rangel
Rodrigo Rangel
DWDavid T. Wu
David T. Wu
Regeneration of the dental, oral, and craniofacial (DOC) complex is challenging because mineralized, soft, vascular, and neural tissues lie side by side, and defects are often large and irregular. Three-dimensional (3D) bioprinting enables fabrication of patient-specific, cell-laden constructs and may offer new regenerative options for complex oral cases. This narrative review summarizes current bioprinting technologies, their applications across DOC tissues, and the barriers to clinical adoption. Inkjet, laser-assisted, light-based, extrusion, and co-axial platforms differ in speed, resolution, cell viability, and cost, while intraoperative bioprinting allows constructs to be printed directly into the defect during surgery. Hydrogel-based bioinks, often loaded with cells or growth factors, support cell delivery and guided differentiation. Across the dentin–pulp complex, periodontium, gingiva, salivary glands, peripheral nerves, cartilage, and craniofacial bone, preclinical studies report that bioprinted constructs can recreate tissue microarchitecture, enhance vascularization, and support partial functional repair. Whole-tooth and load-bearing bone regeneration remain constrained by spatial patterning, vascularization, and mechanical demands. Most evidence remains preclinical, and translation is limited by cost, fragmented workflows, biological and mechanical mismatch at tissue interfaces, and unclear regulatory pathways. Standardized fidelity and viability metrics, improved bioinks, and point-of-care workflows will be needed before bioprinting becomes part of routine oral regenerative care.